FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

1	OMB APPROVAL									
	OMB Number:	3235-0287								
	Estimated average burd	len								
	hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

								(, 0				. 20 .0	1	1.00	<b></b>		/ \			
Name and Address of Reporting Person*     ALEXANDER SUSAN H						2. Issuer Name and Ticker or Trading Symbol BIOGEN INC. [ BIIB ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner						
														Officer	Officer (give title		Other (s			
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year)								below)	,		below)			
BIOGEN INC.						02/15/2020								EVP Chief Legal Off & Corp Sec						
225 BINNEY STREET																				
							4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)													X Form filed by One Reporting Person Form filed by More than One Reporting							
CAMBRIDGE MA 02142																				
(City) (State) (Zip)													Person							
		Tal	ole I - Nor	n-Deri	ivativ	e Se	curi	ties Ac	quired	Dis	posed o	f, or Ber	neficiall	y Owned						
1. Title of Security (Instr. 3) 2. Trans					saction		2A. Deemed Execution Date, if any (Month/Day/Year)		3.	action		ies Acquire Of (D) (Ins		5. Amount of Securities		6. Ownership Form: Direct		7. Nature of Indirect		
					lonth/Day/Year)				Code (Instr. 5)		21 (B) (1115ti. 6, 4 tilla		Beneficially Owned Following		(D) or Indirect (I) (Instr. 4)		Beneficial Ownership			
							<u> </u>		` <del> </del>	V	<u> </u>	(A) or	Price Reported		ı ĭ	.,,		(Instr. 4)		
									Code	Į*	Amount	(D)	Price	(Instr. 3 a						
Common Stock 02/15/						/2020		M		1,553	A	\$0	37,261			D				
Common Stock 02/15/					15/202	/2020		F		689 D		\$333	36,572			D				
			Table II -								osed of,			Owned						
1. Title of	2.	3. Transaction	3A. Deemed		4.	Can	<del>-</del>					7. Title an		8. Price of	9. Number	r of	10.	11. Nature		
Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	n Date	Execution Date, if any (Month/Day/Year	Date,	Transaction Code (Instr.		n Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported Transaction(s)		Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)		
													Amount or		(Instr. 4)	``'				
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Number of Shares							
Restricted Stock Unit	\$0	02/15/2020			M			1,553	(1)		02/15/2020	Common Stock	1,553	\$0	1,171		D			
Restricted Stock Unit	\$0	02/15/2020			J			1,171 <sup>(2)</sup>	(1)		02/15/2020	Common Stock	1,171	\$0	0		D			

## Explanation of Responses:

- 1. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
- 2. This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

/s/ Suzanne Murray, Attorney in Fact for Susan Alexander

02/19/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.